<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797965</url>
  </required_header>
  <id_info>
    <org_study_id>205MS303</org_study_id>
    <secondary_id>2012-003176-39</secondary_id>
    <nct_id>NCT01797965</nct_id>
  </id_info>
  <brief_title>Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability of long-term
      treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants
      with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301
      (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).

      Secondary objectives of this study in this study population are as follows:

      To describe MS-related outcomes, including MS relapse, disability progression, MS lesion
      formation, and participant-reported impact of MS, following long-term treatment with DAC HYP
      To assess the long-term immunogenicity of DAC HYP administered by prefilled syringe (PFS) To
      assess the safety, tolerability, and efficacy of switching to DAC HYP in participants
      previously on long-term treatment with interferon β-1a (Avonex) in Study
      205MS301(NCT01064401).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment will include up to 1600 Participants, this includes approximately 1200
      Participants who completed Study 205MS301 (NCT01064401). Additionally, approximately 400
      Participants from the other BIIB019 extension studies 205MS203 (NCT01051349) and 205MS302
      (NCT01462318) will be eligible to enter Study 205MS303 at Week 144 of Study 205MS303 [Study
      205MS301 (NCT01064401), study 205MS203 (NCT01051349) and study 205MS302 (NCT01462318) have
      been referred to as parent studies in the protocol]. All Participants will receive the same
      dose of DAC HYP as received in the parent studies; i.e., 150 mg by an SC injection every 4
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated because of differences in the participant population under study compared with
    indicated Zinbryta use in most countries.
  </why_stopped>
  <start_date type="Actual">February 15, 2013</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>First dose of study drug in Study 303 to within 180 days of last dose (up to approximately 5.5 years)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR) in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in the 303 study</time_frame>
    <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative multiple sclerosis (MS) medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, Expanded Disability Status Scale (EDSS) (&lt;=2.5 vs &gt;2.5) and age (&lt;=35 vs &gt;35) prior to start of study treatment in 205MS301, calculated using the negative binomial model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARR in the 205MS301-303 Combined Study Period and 205MS301 Treatment Period</measure>
    <time_frame>Up to 5.6 years combining 303 with the initial Study 301; Up to 1 year in the 301 study</time_frame>
    <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative MS medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, EDSS (&lt;=2.5 vs &gt;2.5) and age (&lt;=35 vs &gt;35) prior to start of study treatment in 301, calculated using the negative binomial model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Relapse in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in the 303 study</time_frame>
    <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Relapse in the 205MS301-303 Combined Study Period</measure>
    <time_frame>Up to 5.6 years combining 303 with the initial Study 301</time_frame>
    <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Disability Progression in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in Study 303</time_frame>
    <description>Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period</measure>
    <time_frame>Up to 5.6 years combining 303 with the initial Study 301</time_frame>
    <description>Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
    <description>T2 Hyperintense Lesions were assessed by magnetic resonance imaging (MRI) and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS301 Treatment Period</measure>
    <time_frame>Baseline 301, Weeks 24, 96, 144 in Study 301</time_frame>
    <description>T2 Hyperintense Lesions were assessed by MRI and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 48, 96, 144, 192, 240; 203-303 and 302-303: Week 96</time_frame>
    <description>Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS301 Treatment Period</measure>
    <time_frame>Baseline 301, Weeks 24, 96 and 144</time_frame>
    <description>Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New T1 Hypointense Lesions in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
    <description>T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New T1 Hypointense Lesions in the 205MS301 Treatment Period</measure>
    <time_frame>Baseline 301, Weeks 24, 96, 144 in Study 301</time_frame>
    <description>T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Brain Volume From the 205MS303 Baseline</measure>
    <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
    <description>To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Brain Volume From 205MS301 Baseline</measure>
    <time_frame>Baseline 301, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
    <description>To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of T2 Hyperintense Lesions in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303; 203-303 and 302-303: Week 96</time_frame>
    <description>Volume of T2 hyperintense Lesions was evaluated by MRI and was analyzed by a central MRI reader.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Multiple Sclerosis Functional Composite (MSFC) Score in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 12, 24 and 48 in Study 303</time_frame>
    <description>MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3&quot;). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From 205MS301 Baseline in the MSFC Score in the 205MS301-303 Combined Study Period</measure>
    <time_frame>Baseline 301, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 in the 301 study, Baseline 303, Weeks 12, 24, 48 in the 303 study</time_frame>
    <description>MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3&quot;). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Expanded Disability Status Scale (EDSS) Score in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 260; 203-303 and 302-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 116 in Study 303</time_frame>
    <description>The EDSS measures the disability status of people with multiple sclerosis as assessed by the Study Neurologist based on 8 functional systems that ranges from 0=normal neurologic exam; to 5=ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to 10=death due to MS. Higher scores indicate more disability. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in Study 303</time_frame>
    <description>Participants without clinical or radiological activity are defined as disease-free. Clinical activity includes assessment of relapses and of disease progression. Radiological activity includes assessments of Gd+ lesions and new or enlarging T2 lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Multiple Sclerosis Impact Scale 29 (MSIS 29) Physical and Psychological Scores in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 12, 24, 48, 96, 120 and 144</time_frame>
    <description>The 29-item MSIS-29 is a disease specific participant-reported outcome measure that has been developed and validated to examine the physical (coordination and mobility) and psychological (mental) impact of MS from a participant's perspective; it measures 20 physical items and 9 psychological items. The results for each of the physical and psychological scores are transformed to a score of 0 to 100 (worse state of health). A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the European Quality of Life, 5 Dimensions (EQ 5D) Health Scores in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 96, 120, 144, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48 and 96 in Study 303</time_frame>
    <description>The EQ-5D is a self-administered questionnaire consisting of 5 domains pertaining to specific health state profile : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participants recorded their level of current health for each domain where: 1=no problems, 2=some problem and 3=severe problems. The health score is derived from the individual scores for each of the 5 domains transformed to a score of 0=worst health state to 1=perfect health state. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life as Assessed by the European Quality of Life, Visual Analog Scale (EQ VAS) in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 96, 120, 44, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48 and 96 in Study 303</time_frame>
    <description>The participant rated their current heath state using the EQ VAS 20-centimeter horizontal line from 0 (worst imaginable health state) to 100 (best imaginable health state). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 24, 48, 96, 144, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48, 96 in 303</time_frame>
    <description>Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS301 Treatment Period</measure>
    <time_frame>Baseline 301, Weeks 24, 48, 72, 96, 120 and 144 in 301</time_frame>
    <description>Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction as Assessed by the Participant in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 12, 24, 48, 72, 96, 120 in Study 303</time_frame>
    <description>Participants answered the question: &quot;How satisfied or dissatisfied are you with the ability of the medication to prevent or treat the condition?&quot; using the following scale: Dissatisfied (Extremely dissatisfied, Very dissatisfied, Dissatisfied) or Satisfied (Somewhat satisfied, Satisfied, Very Satisfied and Extremely satisfied). The number of participants in the Dissatisfied and Satisfied categories is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Productivity Questionnaire (HRPQ): Scheduled Work Hours in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded their scheduled work hours. Data is reported by part time or full time employment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Number of Participants Where MS or Its Treatments Resulted in Missed Work in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded whether their MS or its treatments caused them to miss work. Data is reported by part time or full time employment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Hours of Work Missed Due to MS or Its Treatment in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded the hours they missed work due to MS or its treatments. Data is reported by part time or full time employment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Percent Impact on Employment in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participants assessed the percent impact of MS and its treatments on their work output using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything. Data is reported for part time or full time employment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Hours of Household Chores Planned to Perform in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded their planned hours for household chores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Number of Participants Where MS or Its Treatments Kept the Participant From Completing Chores in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded whether MS or its treatments kept them from completing household chores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Hours Not Performing Household Chores Due to MS or Its Treatment in 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded the hours where they were not able to perform household chores due to MS or its treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRPQ: Percent Impact on Performing Household Chores in the 205MS303 Treatment Period</measure>
    <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
    <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant assessed the percent impact of MS and its treatments on how much they accomplished using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Assessments in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in 303</time_frame>
    <description>Clinical Laboratory assessments included tests of hematology, blood chemistry, renal function, and thyroid function. The investigator determined if the results were clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tolerability as Assessed by Participant-reported Injection Site Pain VAS</measure>
    <time_frame>After the first and fourth injections in 303, approximately Week 0 and Week 12</time_frame>
    <description>The VAS is a 10 cm-long horizontal line labeled with 2 extremes of pain at either end: 0 =no pain on the left and 100=very painful on the right. The participant rates their perceived pain of each injection by placing a vertical mark on the line to indicate the level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Local Tolerability Clinician Injection Site Assessment Categories</measure>
    <time_frame>After the first and fourth injections in 303, approximately Week 0 and Week 12</time_frame>
    <description>The investigator assessed the injection site after the first dose and before the fourth dose for the presence of erythema (None, Mild, Moderate, Severe), pigmentation (None, Hypo, Hyper), Induration (None, Mild, Moderate, Severe), Tenderness (None, Mild, Moderate, Severe) and Temperature (Normal, Warm, Hot). The number of participants in each grade is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-BIIB019 Binding Antibodies (ADAbs) in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in the 303 Treatment Period</time_frame>
    <description>Blood samples were collected for ADAbs and were analyzed using a laboratory test. The number of participants ADAb positive at any post-baseline timepoint is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-BIIB019 Neutralizing Antibodies (Nabs) in the 205MS303 Treatment Period</measure>
    <time_frame>Up to 4.6 years in the 303 Treatment Period</time_frame>
    <description>Blood samples were collected for NAbs and were analyzed using a laboratory test. The number of participants NAb positive at any post-baseline timepoint is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From 205MS303 Baseline in the Symbol Digit Modalities Test (SDMT) Score in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 144, 168, 192, 240 in 303</time_frame>
    <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From 205MS301 Baseline in the SDMT Score in the 205MS301-303 Combined Study Period</measure>
    <time_frame>Baseline 301, Weeks 24, 48, 72, 96, 120, 144 in 301; Weeks 144, 168, 192, 216, 240 in 303</time_frame>
    <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS303 Treatment Period</measure>
    <time_frame>Baseline 303, Weeks 12, 24, 48, 120, 144, 168, 192, 216, 240 in 303</time_frame>
    <description>The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS301-303 Combined Study Period</measure>
    <time_frame>Baseline 301, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 in the 301 study, Baseline 303, Weeks 12, 24, 48, 120, 144,168, 192, 216, 240 in 303 study</time_frame>
    <description>The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1501</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>BIIB019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIIB019 150 mg subcutaneous (SC) every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB019 (Daclizumab)</intervention_name>
    <description>Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.</description>
    <arm_group_label>BIIB019</arm_group_label>
    <other_name>Daclizumab High Yield Process</other_name>
    <other_name>DAC HYP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must be a subject currently participating in Study 205MS301 (NCT01064401), or subject
             currently participating in Study 205MS203 (NCT01051349) or Study 205MS302
             (NCT01462318) who has completed End of Study Visit (Week 96 or later).

          -  Women of childbearing potential must practice effective contraception during the study
             and be willing and able to continue contraception for 4 months after their last dose
             of study treatment.

        Key Exclusion Criteria:

          -  Any subject who permanently discontinued study treatment in Study 205MS301
             (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318) prior to
             the end of the study treatment period, or had an Early Termination visit in Study
             205MS301, Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).

          -  Any significant change in the subject's medical history that would preclude
             administration of BIIB019, including laboratory tests or a current clinically
             significant condition that, in the opinion of the Investigator, would have excluded
             the subject's participation in Study 205MS301 (NCT01064401), Study 205MS203
             (NCT01051349) or Study 205MS302 (NCT01462318).

        The Investigator must re review the subject's medical fitness for participation and
        consider any factors that would preclude treatment in this Study 205MS303.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wellesley</city>
        <state>Massachusetts</state>
        <zip>02481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>﻿01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1015ABR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1061ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Godoy Cruz</city>
        <state>Mendoza</state>
        <zip>M5501</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000BZL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>52010-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20270-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21941-590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <state>Jihomoravský Kraj</state>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <state>Jihomoravský Kraj</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <state>Kray Vysocina</state>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <state>Moravskoslezský Kraj</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <state>Pardubický Kraj</state>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 10</city>
        <state>Praha</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <state>Praha</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <state>Severomoravsky Kraj</state>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <state>Ústecký Kraj</state>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bobigny</city>
        <state>Ile-de-France</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <state>Baden-Württemberg</state>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayreuth</city>
        <state>Bayern</state>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>﻿01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>Macedonia</state>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abaúj-Zemplén</state>
        <zip>3533</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemét</city>
        <state>Bács-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Székesfehérvár</city>
        <state>Fejer</state>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gurgaon</city>
        <zip>122002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>DU04</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>DU09</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cefalù</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>﻿00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>﻿00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Distrito Federal</city>
        <zip>﻿03310</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Distrito Federal</city>
        <zip>﻿06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chisinau</city>
        <zip>MD 2001</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chisinau</city>
        <zip>MD 2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <state>Lódzkie</state>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>﻿00-901</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>﻿02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>﻿02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>﻿02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>﻿04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <state>Swietokrzyskie</state>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-443</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plewiska</city>
        <state>Wielkopolskie</state>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-684</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj- Napoca</city>
        <state>Cluj</state>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Târgu Mures</city>
        <state>Mures</state>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>﻿011461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700656</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavlr</state>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyumen</city>
        <zip>625000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>﻿08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>14008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Communidad Delaware</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>l'Hospitalet de Llobregat</city>
        <zip>﻿08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmö</city>
        <state>Skane</state>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <state>Sodermanlands Lan</state>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <state>Sodermanlands Lan</state>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <state>Vastra Gotalands Lan</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt (de)</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <state>Chernivets'ka Oblast</state>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovs'ka Oblast'</state>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <state>Donets'ka Oblast'</state>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivs'ka Oblast'</state>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <state>Kyïv</state>
        <zip>﻿02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <state>Kyïv</state>
        <zip>﻿03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <state>Kyïv</state>
        <zip>﻿04060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <state>Odes'ka Oblast</state>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <state>Poltavs'ka Oblast</state>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporiz'ka Oblast'</state>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporizhia Oblast</state>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <state>Edinburgh, City Of</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Finland</country>
  </removed_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>November 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2019</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daclizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01797965/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01797965/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in the study at 226 investigative sites in 28 countries (United States, Canada, Western European countries, Australia, Israel, Eastern European countries, Argentina, Brazil, India, and Mexico) from 15 February 2013 to 24 September 2018.</recruitment_details>
      <pre_assignment_details>Participants who completed studies: 205MS301 (NCT01064401), 205MS203 (NCT01051349), 205MS302 (NCT01462318) were eligible to enroll in this long-term extension study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
        </group>
        <group group_id="P2">
          <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
          <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
        </group>
        <group group_id="P3">
          <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
        </group>
        <group group_id="P4">
          <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94. 1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="597"/>
                <participants group_id="P2" count="607"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="549"/>
                <participants group_id="P2" count="569"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression, defined by protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="295"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants who completed Study 301, 302 or 203 and received at least 1 dose of DAC HYP during Study 303.</population>
      <group_list>
        <group group_id="B1">
          <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
        </group>
        <group group_id="B2">
          <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
          <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
        </group>
        <group group_id="B3">
          <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
        </group>
        <group group_id="B4">
          <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94. 1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="597"/>
            <count group_id="B2" value="606"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="227"/>
            <count group_id="B5" value="1500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Adults (18-64 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="597"/>
                    <measurement group_id="B2" value="606"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="227"/>
                    <measurement group_id="B5" value="1500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="394"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="966"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                    <measurement group_id="B2" value="559"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="223"/>
                    <measurement group_id="B5" value="1330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>First dose of study drug in Study 303 to within 180 days of last dose (up to approximately 5.5 years)</time_frame>
        <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and had at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
          <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and had at least 1 dose of DAC HYP during Study 303.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541"/>
                    <measurement group_id="O2" value="560"/>
                    <measurement group_id="O3" value="172"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate (ARR) in the 205MS303 Treatment Period</title>
        <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative multiple sclerosis (MS) medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, Expanded Disability Status Scale (EDSS) (&lt;=2.5 vs &gt;2.5) and age (&lt;=35 vs &gt;35) prior to start of study treatment in 205MS301, calculated using the negative binomial model.</description>
        <time_frame>Up to 4.6 years in the 303 study</time_frame>
        <population>Intent-to-treat (ITT) Population consisted of all participants who completed Study 301, 203 or 302 and received at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate (ARR) in the 205MS303 Treatment Period</title>
          <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative multiple sclerosis (MS) medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, Expanded Disability Status Scale (EDSS) (&lt;=2.5 vs &gt;2.5) and age (&lt;=35 vs &gt;35) prior to start of study treatment in 205MS301, calculated using the negative binomial model.</description>
          <population>Intent-to-treat (ITT) Population consisted of all participants who completed Study 301, 203 or 302 and received at least 1 dose of DAC HYP during Study 303.</population>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" lower_limit="0.134" upper_limit="0.188"/>
                    <measurement group_id="O2" value="0.163" lower_limit="0.138" upper_limit="0.193"/>
                    <measurement group_id="O3" value="0.080" lower_limit="0.047" upper_limit="0.136"/>
                    <measurement group_id="O4" value="0.167" lower_limit="0.097" upper_limit="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ARR in the 205MS301-303 Combined Study Period and 205MS301 Treatment Period</title>
        <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative MS medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, EDSS (&lt;=2.5 vs &gt;2.5) and age (&lt;=35 vs &gt;35) prior to start of study treatment in 301, calculated using the negative binomial model.</description>
        <time_frame>Up to 5.6 years combining 303 with the initial Study 301; Up to 1 year in the 301 study</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ARR in the 205MS301-303 Combined Study Period and 205MS301 Treatment Period</title>
          <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist. The unadjusted ARR was calculated by tabulating the total number of relapses experienced in the group divided by the number of days up to the end of study, and the ratio then multiplied by 365.25. Relapses that occurred after participants received alternative MS medications were excluded from the analyses. ARR was adjusted for relapse rate, IFN beta use, EDSS (&lt;=2.5 vs &gt;2.5) and age (&lt;=35 vs &gt;35) prior to start of study treatment in 301, calculated using the negative binomial model.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303.</population>
          <units>relapses per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>301-303 Combined Study Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.247" lower_limit="0.220" upper_limit="0.279"/>
                    <measurement group_id="O2" value="0.175" lower_limit="0.154" upper_limit="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>301 Treatment Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.317" lower_limit="0.280" upper_limit="0.360"/>
                    <measurement group_id="O2" value="0.195" lower_limit="0.169" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Relapse in the 205MS303 Treatment Period</title>
        <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.</description>
        <time_frame>Up to 4.6 years in the 303 study</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and had at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse in the 205MS303 Treatment Period</title>
          <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and had at least 1 dose of DAC HYP during Study 303.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="172"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Relapse in the 205MS301-303 Combined Study Period</title>
        <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.</description>
        <time_frame>Up to 5.6 years combining 303 with the initial Study 301</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and had at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse in the 205MS301-303 Combined Study Period</title>
          <description>Relapses are defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Study Neurologist.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and had at least 1 dose of DAC HYP during Study 303.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Disability Progression in the 205MS303 Treatment Period</title>
        <description>Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.</description>
        <time_frame>Up to 4.6 years in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and had at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Disability Progression in the 205MS303 Treatment Period</title>
          <description>Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and had at least 1 dose of DAC HYP during Study 303.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period</title>
        <description>Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.</description>
        <time_frame>Up to 5.6 years combining 303 with the initial Study 301</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and had at least 1 dose of DAC HYP during Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period</title>
          <description>Sustained disability progression is defined as at least a 1.0-point increase on the Expanded Disability Status Scale (EDSS) from 303 baseline EDSS ≥1.0 that is sustained for 24 weeks, or at least a 1.5-point increase on the EDSS from 303 baseline EDSS of 0, that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) =normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Higher scores indicate more disability.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and had at least 1 dose of DAC HYP during Study 303.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS303 Treatment Period</title>
        <description>T2 Hyperintense Lesions were assessed by magnetic resonance imaging (MRI) and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.</description>
        <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
        <population>301-303 ITT population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. No data was collected for participants from the 203 and 302 studies. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS303 Treatment Period</title>
          <description>T2 Hyperintense Lesions were assessed by magnetic resonance imaging (MRI) and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.</description>
          <population>301-303 ITT population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. No data was collected for participants from the 203 and 302 studies. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS301 Treatment Period</title>
        <description>T2 Hyperintense Lesions were assessed by MRI and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported.</description>
        <time_frame>Baseline 301, Weeks 24, 96, 144 in Study 301</time_frame>
        <population>301-303 ITT population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS301 Treatment Period</title>
          <description>T2 Hyperintense Lesions were assessed by MRI and were analyzed by a central MRI reader. The number of participants with New or Newly Enlarging T2 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported.</description>
          <population>301-303 ITT population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="595"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="587"/>
                    <count group_id="O2" value="590"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435"/>
                    <measurement group_id="O2" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS303 Treatment Period</title>
        <description>Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.</description>
        <time_frame>301-303: Baseline 303, Weeks 48, 96, 144, 192, 240; 203-303 and 302-303: Week 96</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAY HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS303 Treatment Period</title>
          <description>Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAY HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="591"/>
                    <count group_id="O2" value="590"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="533"/>
                    <count group_id="O2" value="510"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="353"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="374"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS301 Treatment Period</title>
        <description>Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.</description>
        <time_frame>Baseline 301, Weeks 24, 96 and 144</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAY HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS301 Treatment Period</title>
          <description>Gd+ lesions were evaluated by MRI and were analyzed by a central MRI reader.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAY HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="591"/>
                    <count group_id="O2" value="595"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="598"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New T1 Hypointense Lesions in the 205MS303 Treatment Period</title>
        <description>T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.</description>
        <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected from participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New T1 Hypointense Lesions in the 205MS303 Treatment Period</title>
          <description>T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 303 Baseline in the 303 Treatment Period is reported.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected from participants from the 203 and 302 studies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="531"/>
                    <count group_id="O2" value="510"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="374"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New T1 Hypointense Lesions in the 205MS301 Treatment Period</title>
        <description>T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported .</description>
        <time_frame>Baseline 301, Weeks 24, 96, 144 in Study 301</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New T1 Hypointense Lesions in the 205MS301 Treatment Period</title>
          <description>T1 hypointense lesions were evaluated by MRI and were analyzed by a central MRI reader. The number of participants with New T1 Hyperintense Lesions relative to the 301 Baseline in the 301 Treatment Period is reported .</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="594"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="584"/>
                    <count group_id="O2" value="588"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Brain Volume From the 205MS303 Baseline</title>
        <description>To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.</description>
        <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Brain Volume From the 205MS303 Baseline</title>
          <description>To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.451" spread="0.5917"/>
                    <measurement group_id="O2" value="-0.355" spread="0.5100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.713" spread="0.7288"/>
                    <measurement group_id="O2" value="-0.549" spread="0.6126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="290"/>
                    <count group_id="O2" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.050" spread="0.8566"/>
                    <measurement group_id="O2" value="-0.801" spread="0.7145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.225" spread="1.0139"/>
                    <measurement group_id="O2" value="-0.967" spread="0.8772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.261" spread="1.0382"/>
                    <measurement group_id="O2" value="-0.852" spread="0.9890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Brain Volume From 205MS301 Baseline</title>
        <description>To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.</description>
        <time_frame>Baseline 301, Weeks 48, 96, 144, 192, 240 in Study 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Brain Volume From 205MS301 Baseline</title>
          <description>To assess brain atrophy, total brain volume was measured by MRI and was analyzed by a central MRI reader. A negative percent change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 303 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="462"/>
                    <count group_id="O2" value="427"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.535" spread="1.1975"/>
                    <measurement group_id="O2" value="-1.409" spread="1.1538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.871" spread="1.3720"/>
                    <measurement group_id="O2" value="-1.595" spread="1.0736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="333"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.165" spread="1.4596"/>
                    <measurement group_id="O2" value="-1.812" spread="1.2044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                    <count group_id="O2" value="261"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.403" spread="1.6088"/>
                    <measurement group_id="O2" value="-1.970" spread="1.3439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.415" spread="1.6005"/>
                    <measurement group_id="O2" value="-1.922" spread="1.2258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of T2 Hyperintense Lesions in the 205MS303 Treatment Period</title>
        <description>Volume of T2 hyperintense Lesions was evaluated by MRI and was analyzed by a central MRI reader.</description>
        <time_frame>Baseline 303, Weeks 48, 96, 144, 192, 240 in Study 303; 203-303 and 302-303: Week 96</time_frame>
        <population>ITT Population included all participants who completed Study 301, 203 or 302 and received at least 1 dose of DAC HYP in Study 303. Number Analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of T2 Hyperintense Lesions in the 205MS303 Treatment Period</title>
          <description>Volume of T2 hyperintense Lesions was evaluated by MRI and was analyzed by a central MRI reader.</description>
          <population>ITT Population included all participants who completed Study 301, 203 or 302 and received at least 1 dose of DAC HYP in Study 303. Number Analyzed is the number of participants with data available at the given timepoint.</population>
          <units>millimeters cubed (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="592"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10357.54" spread="11977.864"/>
                    <measurement group_id="O2" value="9323.33" spread="10777.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="499"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10738.32" spread="12358.857"/>
                    <measurement group_id="O2" value="9524.23" spread="10822.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="376"/>
                    <count group_id="O2" value="345"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11498.94" spread="12769.813"/>
                    <measurement group_id="O2" value="10018.09" spread="11432.768"/>
                    <measurement group_id="O3" value="16116.01" spread="16791.388"/>
                    <measurement group_id="O4" value="12627.51" spread="14777.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="370"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11242.79" spread="12838.060"/>
                    <measurement group_id="O2" value="10265.04" spread="11324.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="267"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12453.96" spread="13643.373"/>
                    <measurement group_id="O2" value="10662.66" spread="11815.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9368.05" spread="12428.209"/>
                    <measurement group_id="O2" value="9230.78" spread="11395.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Multiple Sclerosis Functional Composite (MSFC) Score in the 205MS303 Treatment Period</title>
        <description>MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3&quot;). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline 303, Weeks 12, 24 and 48 in Study 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected from participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Multiple Sclerosis Functional Composite (MSFC) Score in the 205MS303 Treatment Period</title>
          <description>MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3&quot;). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected from participants from the 203 and 302 studies.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24958" lower_limit="-5.5818" upper_limit="1.2110"/>
                    <measurement group_id="O2" value="0.30019" lower_limit="-6.1660" upper_limit="1.5643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="584"/>
                    <count group_id="O2" value="583"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00010" lower_limit="-3.3934" upper_limit="1.6147"/>
                    <measurement group_id="O2" value="-0.01021" lower_limit="-4.5948" upper_limit="0.9577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="564"/>
                    <count group_id="O2" value="554"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00599" lower_limit="-2.7855" upper_limit="1.6913"/>
                    <measurement group_id="O2" value="-0.00010" lower_limit="-3.4062" upper_limit="1.3673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="529"/>
                    <count group_id="O2" value="507"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01026" lower_limit="-3.7220" upper_limit="1.7775"/>
                    <measurement group_id="O2" value="-0.01897" lower_limit="-3.5941" upper_limit="1.4111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5937</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6233</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1884</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From 205MS301 Baseline in the MSFC Score in the 205MS301-303 Combined Study Period</title>
        <description>MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3&quot;). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline 301, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 in the 301 study, Baseline 303, Weeks 12, 24, 48 in the 303 study</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed: Number of participants with data available at given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From 205MS301 Baseline in the MSFC Score in the 205MS301-303 Combined Study Period</title>
          <description>MSFC is a three-part, standardized, quantitative, assessment instrument consisting of (Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) and Paced Auditory Serial Addition Test (PASAT-3&quot;). 2 timed 25-foot walk scores are averaged. 4 trials of the Peg Test (2 for each hand) are converted to the reciprocals and averaged. The number correct of the PASAT-3 is used. The composite Z-score is calculated by: Z(25-foot walk) + Z (HPT) + Z(PASAT)/3. A positive change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed: Number of participants with data available at given timepoint.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="605"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14629" lower_limit="-6.4963" upper_limit="1.3731"/>
                    <measurement group_id="O2" value="0.14298" lower_limit="-2.9163" upper_limit="1.3865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 12 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="603"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00133" lower_limit="-1.8674" upper_limit="6.4516"/>
                    <measurement group_id="O2" value="0.02593" lower_limit="-1.7953" upper_limit="2.3905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 24 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="594"/>
                    <count group_id="O2" value="599"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02377" lower_limit="-1.9966" upper_limit="6.2712"/>
                    <measurement group_id="O2" value="0.04728" lower_limit="-4.3661" upper_limit="2.1389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 36 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="597"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04764" lower_limit="-3.0131" upper_limit="6.2565"/>
                    <measurement group_id="O2" value="0.05771" lower_limit="-11.0047" upper_limit="2.1389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 48 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="601"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06491" lower_limit="-1.6103" upper_limit="6.5816"/>
                    <measurement group_id="O2" value="0.07793" lower_limit="-1.3713" upper_limit="2.1024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 60 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="598"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06893" lower_limit="-4.4756" upper_limit="6.6543"/>
                    <measurement group_id="O2" value="0.08973" lower_limit="-1.3564" upper_limit="1.9165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 72 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08645" lower_limit="-3.7849" upper_limit="6.7127"/>
                    <measurement group_id="O2" value="0.08690" lower_limit="-5.6579" upper_limit="2.0135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 84 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="591"/>
                    <count group_id="O2" value="597"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05704" lower_limit="-4.3418" upper_limit="6.6940"/>
                    <measurement group_id="O2" value="0.10283" lower_limit="-5.4012" upper_limit="2.0493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 96 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06731" lower_limit="-4.1506" upper_limit="6.8296"/>
                    <measurement group_id="O2" value="0.11283" lower_limit="-5.8373" upper_limit="2.2536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 108 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="489"/>
                    <count group_id="O2" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08020" lower_limit="-4.8814" upper_limit="6.8182"/>
                    <measurement group_id="O2" value="0.09868" lower_limit="-5.0171" upper_limit="2.4199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 120 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08406" lower_limit="-4.4964" upper_limit="6.8441"/>
                    <measurement group_id="O2" value="0.10367" lower_limit="-3.4544" upper_limit="1.2502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 132 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="289"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07712" lower_limit="-4.6292" upper_limit="3.6137"/>
                    <measurement group_id="O2" value="0.08682" lower_limit="-3.9359" upper_limit="3.2500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 144 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09674" lower_limit="-2.1875" upper_limit="4.0089"/>
                    <measurement group_id="O2" value="0.12943" lower_limit="-0.8767" upper_limit="1.2626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 156 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.0272" lower_limit="-0.0272" upper_limit="-0.0272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="595"/>
                    <count group_id="O2" value="603"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06638" lower_limit="-1.9364" upper_limit="6.8441"/>
                    <measurement group_id="O2" value="0.11003" lower_limit="-5.0171" upper_limit="3.3811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 12 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06449" lower_limit="-2.8537" upper_limit="6.9351"/>
                    <measurement group_id="O2" value="0.09616" lower_limit="-5.3094" upper_limit="3.3600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 24 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="562"/>
                    <count group_id="O2" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07140" lower_limit="-2.7241" upper_limit="6.7870"/>
                    <measurement group_id="O2" value="0.12955" lower_limit="-5.0936" upper_limit="3.2141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 48 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="527"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05533" lower_limit="-2.8215" upper_limit="7.0425"/>
                    <measurement group_id="O2" value="0.09332" lower_limit="-5.3475" upper_limit="3.3180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 12 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0204</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 24 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0805</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 36 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2535</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 48 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4738</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 60 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2302</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 72 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8522</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 84 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0431</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 96 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0339</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 108 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3195</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 120 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2119</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 132 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3619</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 144 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0170</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Baseline 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0170</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 12 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0849</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 24 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 48 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3960</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline Z-score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Expanded Disability Status Scale (EDSS) Score in the 205MS303 Treatment Period</title>
        <description>The EDSS measures the disability status of people with multiple sclerosis as assessed by the Study Neurologist based on 8 functional systems that ranges from 0=normal neurologic exam; to 5=ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to 10=death due to MS. Higher scores indicate more disability. A negative change from Baseline indicates improvement.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 260; 203-303 and 302-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 116 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Expanded Disability Status Scale (EDSS) Score in the 205MS303 Treatment Period</title>
          <description>The EDSS measures the disability status of people with multiple sclerosis as assessed by the Study Neurologist based on 8 functional systems that ranges from 0=normal neurologic exam; to 5=ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to 10=death due to MS. Higher scores indicate more disability. A negative change from Baseline indicates improvement.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="595"/>
                    <count group_id="O2" value="605"/>
                    <count group_id="O3" value="226"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.468"/>
                    <measurement group_id="O2" value="2.44" spread="1.409"/>
                    <measurement group_id="O3" value="2.86" spread="1.500"/>
                    <measurement group_id="O4" value="2.56" spread="1.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="592"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.464"/>
                    <measurement group_id="O2" value="0.02" spread="0.467"/>
                    <measurement group_id="O3" value="0.14" spread="0.244"/>
                    <measurement group_id="O4" value="0.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="581"/>
                    <count group_id="O3" value="223"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.570"/>
                    <measurement group_id="O2" value="0.03" spread="0.480"/>
                    <measurement group_id="O3" value="0.02" spread="0.237"/>
                    <measurement group_id="O4" value="-0.06" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="551"/>
                    <count group_id="O2" value="541"/>
                    <count group_id="O3" value="215"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.614"/>
                    <measurement group_id="O2" value="0.06" spread="0.495"/>
                    <measurement group_id="O3" value="0.00" spread="0.349"/>
                    <measurement group_id="O4" value="-0.05" spread="0.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="520"/>
                    <count group_id="O2" value="495"/>
                    <count group_id="O3" value="204"/>
                    <count group_id="O4" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.670"/>
                    <measurement group_id="O2" value="0.10" spread="0.548"/>
                    <measurement group_id="O3" value="0.04" spread="0.378"/>
                    <measurement group_id="O4" value="0.00" spread="0.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="469"/>
                    <count group_id="O3" value="193"/>
                    <count group_id="O4" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.729"/>
                    <measurement group_id="O2" value="0.13" spread="0.602"/>
                    <measurement group_id="O3" value="0.04" spread="0.400"/>
                    <measurement group_id="O4" value="0.01" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 116</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.05" spread="0.353"/>
                    <measurement group_id="O4" value="0.11" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="453"/>
                    <count group_id="O2" value="441"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.768"/>
                    <measurement group_id="O2" value="0.11" spread="0.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="417"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.742"/>
                    <measurement group_id="O2" value="0.17" spread="0.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.798"/>
                    <measurement group_id="O2" value="0.19" spread="0.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="348"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.756"/>
                    <measurement group_id="O2" value="0.22" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="315"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.775"/>
                    <measurement group_id="O2" value="0.22" spread="0.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="223"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.789"/>
                    <measurement group_id="O2" value="0.26" spread="0.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.007"/>
                    <measurement group_id="O2" value="-0.17" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period</title>
        <description>Participants without clinical or radiological activity are defined as disease-free. Clinical activity includes assessment of relapses and of disease progression. Radiological activity includes assessments of Gd+ lesions and new or enlarging T2 lesions.</description>
        <time_frame>Up to 4.6 years in Study 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. No data was collected for participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period</title>
          <description>Participants without clinical or radiological activity are defined as disease-free. Clinical activity includes assessment of relapses and of disease progression. Radiological activity includes assessments of Gd+ lesions and new or enlarging T2 lesions.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. No data was collected for participants from the 203 and 302 studies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8417</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for the baseline relapse rate, history of prior IFN beta use (yes/no), baseline EDSS (&lt;=2.5 vs &gt;2.5) and baseline age (&lt;=35 vs &gt;35).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.902</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.329</ci_lower_limit>
            <ci_upper_limit>2.473</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Multiple Sclerosis Impact Scale 29 (MSIS 29) Physical and Psychological Scores in the 205MS303 Treatment Period</title>
        <description>The 29-item MSIS-29 is a disease specific participant-reported outcome measure that has been developed and validated to examine the physical (coordination and mobility) and psychological (mental) impact of MS from a participant's perspective; it measures 20 physical items and 9 psychological items. The results for each of the physical and psychological scores are transformed to a score of 0 to 100 (worse state of health). A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline 303, Weeks 12, 24, 48, 96, 120 and 144</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Multiple Sclerosis Impact Scale 29 (MSIS 29) Physical and Psychological Scores in the 205MS303 Treatment Period</title>
          <description>The 29-item MSIS-29 is a disease specific participant-reported outcome measure that has been developed and validated to examine the physical (coordination and mobility) and psychological (mental) impact of MS from a participant's perspective; it measures 20 physical items and 9 psychological items. The results for each of the physical and psychological scores are transformed to a score of 0 to 100 (worse state of health). A negative change from Baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Scores: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="597"/>
                    <count group_id="O2" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.61" spread="20.134"/>
                    <measurement group_id="O2" value="19.19" spread="19.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Scores: Change to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="11.114"/>
                    <measurement group_id="O2" value="-0.28" spread="9.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Scores: Change to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="10.313"/>
                    <measurement group_id="O2" value="-0.88" spread="9.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Scores: Change to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="531"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="11.178"/>
                    <measurement group_id="O2" value="0.13" spread="9.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Scores: Change to Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="12.713"/>
                    <measurement group_id="O2" value="0.48" spread="10.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Scores: Change to Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="9.062"/>
                    <measurement group_id="O2" value="1.44" spread="10.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Scores: Change to Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0"/>
                    <measurement group_id="O2" value="-5.00" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="597"/>
                    <count group_id="O2" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.46" spread="21.310"/>
                    <measurement group_id="O2" value="22.37" spread="20.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Change to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="12.501"/>
                    <measurement group_id="O2" value="-0.34" spread="11.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Change to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="14.154"/>
                    <measurement group_id="O2" value="-1.69" spread="11.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Change to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="531"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="14.865"/>
                    <measurement group_id="O2" value="0.10" spread="13.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Change to Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="13.923"/>
                    <measurement group_id="O2" value="-0.89" spread="14.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Change to Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="10.105"/>
                    <measurement group_id="O2" value="0.00" spread="8.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological Scores: Change to Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="0"/>
                    <measurement group_id="O2" value="-13.89" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the European Quality of Life, 5 Dimensions (EQ 5D) Health Scores in the 205MS303 Treatment Period</title>
        <description>The EQ-5D is a self-administered questionnaire consisting of 5 domains pertaining to specific health state profile : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participants recorded their level of current health for each domain where: 1=no problems, 2=some problem and 3=severe problems. The health score is derived from the individual scores for each of the 5 domains transformed to a score of 0=worst health state to 1=perfect health state. A positive change from Baseline indicates improvement.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 96, 120, 144, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48 and 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the European Quality of Life, 5 Dimensions (EQ 5D) Health Scores in the 205MS303 Treatment Period</title>
          <description>The EQ-5D is a self-administered questionnaire consisting of 5 domains pertaining to specific health state profile : mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participants recorded their level of current health for each domain where: 1=no problems, 2=some problem and 3=severe problems. The health score is derived from the individual scores for each of the 5 domains transformed to a score of 0=worst health state to 1=perfect health state. A positive change from Baseline indicates improvement.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="597"/>
                    <count group_id="O2" value="606"/>
                    <count group_id="O3" value="227"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.233"/>
                    <measurement group_id="O2" value="0.79" spread="0.201"/>
                    <measurement group_id="O3" value="0.71" spread="0.242"/>
                    <measurement group_id="O4" value="0.77" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="600"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.168"/>
                    <measurement group_id="O2" value="-0.01" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="574"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.171"/>
                    <measurement group_id="O2" value="0.00" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="553"/>
                    <count group_id="O2" value="531"/>
                    <count group_id="O3" value="225"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.185"/>
                    <measurement group_id="O2" value="-0.01" spread="0.152"/>
                    <measurement group_id="O3" value="0.00" spread="0.164"/>
                    <measurement group_id="O4" value="0.00" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="497"/>
                    <count group_id="O2" value="472"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.168"/>
                    <measurement group_id="O2" value="-0.02" spread="0.170"/>
                    <measurement group_id="O3" value="-0.01" spread="0.162"/>
                    <measurement group_id="O4" value="0.00" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="448"/>
                    <count group_id="O2" value="431"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.166"/>
                    <measurement group_id="O2" value="-0.01" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="416"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.187"/>
                    <measurement group_id="O2" value="-0.02" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.187"/>
                    <measurement group_id="O2" value="-0.03" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.154"/>
                    <measurement group_id="O2" value="-0.06" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life as Assessed by the European Quality of Life, Visual Analog Scale (EQ VAS) in the 205MS303 Treatment Period</title>
        <description>The participant rated their current heath state using the EQ VAS 20-centimeter horizontal line from 0 (worst imaginable health state) to 100 (best imaginable health state). A positive change from baseline indicates improvement.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 96, 120, 44, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48 and 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life as Assessed by the European Quality of Life, Visual Analog Scale (EQ VAS) in the 205MS303 Treatment Period</title>
          <description>The participant rated their current heath state using the EQ VAS 20-centimeter horizontal line from 0 (worst imaginable health state) to 100 (best imaginable health state). A positive change from baseline indicates improvement.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="597"/>
                    <count group_id="O2" value="606"/>
                    <count group_id="O3" value="227"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.19" spread="19.534"/>
                    <measurement group_id="O2" value="77.74" spread="19.144"/>
                    <measurement group_id="O3" value="72.13" spread="21.154"/>
                    <measurement group_id="O4" value="76.97" spread="19.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="595"/>
                    <count group_id="O2" value="598"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="12.753"/>
                    <measurement group_id="O2" value="0.25" spread="12.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="581"/>
                    <count group_id="O2" value="574"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="12.135"/>
                    <measurement group_id="O2" value="0.74" spread="11.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="531"/>
                    <count group_id="O3" value="222"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="12.966"/>
                    <measurement group_id="O2" value="-0.35" spread="13.543"/>
                    <measurement group_id="O3" value="-1.50" spread="13.604"/>
                    <measurement group_id="O4" value="-0.64" spread="13.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="497"/>
                    <count group_id="O2" value="472"/>
                    <count group_id="O3" value="190"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="14.963"/>
                    <measurement group_id="O2" value="0.56" spread="12.054"/>
                    <measurement group_id="O3" value="0.45" spread="11.724"/>
                    <measurement group_id="O4" value="-0.95" spread="11.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="448"/>
                    <count group_id="O2" value="430"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="13.406"/>
                    <measurement group_id="O2" value="1.52" spread="13.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="416"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="14.263"/>
                    <measurement group_id="O2" value="1.64" spread="13.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="338"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="15.058"/>
                    <measurement group_id="O2" value="0.66" spread="14.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="11.318"/>
                    <measurement group_id="O2" value="-1.53" spread="13.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS303 Treatment Period</title>
        <description>Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.</description>
        <time_frame>301-303: Baseline 303, Weeks 24, 48, 96, 144, 192, 240; 203-303 and 302-303: Baseline 303, Weeks 48, 96 in 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS303 Treatment Period</title>
          <description>Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>site visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MS-related Site Visits: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="557"/>
                    <count group_id="O2" value="549"/>
                    <count group_id="O3" value="201"/>
                    <count group_id="O4" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="491"/>
                    <count group_id="O2" value="492"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="491"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="191"/>
                    <count group_id="O4" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="441"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="319"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="557"/>
                    <count group_id="O2" value="549"/>
                    <count group_id="O3" value="201"/>
                    <count group_id="O4" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="491"/>
                    <count group_id="O2" value="492"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="491"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="191"/>
                    <count group_id="O4" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="441"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="174"/>
                    <count group_id="O4" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="378"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="319"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-MS related Site Visits: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS301 Treatment Period</title>
        <description>Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.</description>
        <time_frame>Baseline 301, Weeks 24, 48, 72, 96, 120 and 144 in 301</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS301 Treatment Period</title>
          <description>Heath resource utilization was assessed by the number of hospitalizations, emergency room visits, and unscheduled neurologist visits for MS-related and non-MS-related visits.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>site visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MS-related Site Visits: Baseline 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="410"/>
                    <count group_id="O2" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="434"/>
                    <count group_id="O2" value="425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS-related Site Visits: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Baseline 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="440"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="410"/>
                    <count group_id="O2" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="412"/>
                    <count group_id="O2" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="434"/>
                    <count group_id="O2" value="425"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non MS-related Site Visits: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction as Assessed by the Participant in the 205MS303 Treatment Period</title>
        <description>Participants answered the question: &quot;How satisfied or dissatisfied are you with the ability of the medication to prevent or treat the condition?&quot; using the following scale: Dissatisfied (Extremely dissatisfied, Very dissatisfied, Dissatisfied) or Satisfied (Somewhat satisfied, Satisfied, Very Satisfied and Extremely satisfied). The number of participants in the Dissatisfied and Satisfied categories is reported.</description>
        <time_frame>Baseline 303, Weeks 12, 24, 48, 72, 96, 120 in Study 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction as Assessed by the Participant in the 205MS303 Treatment Period</title>
          <description>Participants answered the question: &quot;How satisfied or dissatisfied are you with the ability of the medication to prevent or treat the condition?&quot; using the following scale: Dissatisfied (Extremely dissatisfied, Very dissatisfied, Dissatisfied) or Satisfied (Somewhat satisfied, Satisfied, Very Satisfied and Extremely satisfied). The number of participants in the Dissatisfied and Satisfied categories is reported.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dissatisfied: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="592"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="584"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="559"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="507"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="503"/>
                    <count group_id="O2" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="592"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529"/>
                    <measurement group_id="O2" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="586"/>
                    <count group_id="O2" value="584"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540"/>
                    <measurement group_id="O2" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="569"/>
                    <count group_id="O2" value="559"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525"/>
                    <measurement group_id="O2" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="507"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498"/>
                    <measurement group_id="O2" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="503"/>
                    <count group_id="O2" value="472"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476"/>
                    <measurement group_id="O2" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Productivity Questionnaire (HRPQ): Scheduled Work Hours in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded their scheduled work hours. Data is reported by part time or full time employment.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Productivity Questionnaire (HRPQ): Scheduled Work Hours in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded their scheduled work hours. Data is reported by part time or full time employment.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" spread="10.60"/>
                    <measurement group_id="O2" value="19.5" spread="11.45"/>
                    <measurement group_id="O3" value="23.6" spread="9.46"/>
                    <measurement group_id="O4" value="20.2" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="10.30"/>
                    <measurement group_id="O2" value="22.4" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="12.80"/>
                    <measurement group_id="O2" value="20.6" spread="13.47"/>
                    <measurement group_id="O3" value="23.5" spread="9.37"/>
                    <measurement group_id="O4" value="24.5" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="11.12"/>
                    <measurement group_id="O2" value="21.9" spread="11.28"/>
                    <measurement group_id="O3" value="22.7" spread="11.23"/>
                    <measurement group_id="O4" value="27.7" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="12.44"/>
                    <measurement group_id="O2" value="23.0" spread="11.64"/>
                    <measurement group_id="O3" value="22.8" spread="11.60"/>
                    <measurement group_id="O4" value="25.2" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="17.40"/>
                    <measurement group_id="O2" value="19.9" spread="11.79"/>
                    <measurement group_id="O3" value="24.8" spread="10.13"/>
                    <measurement group_id="O4" value="23.5" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="16.13"/>
                    <measurement group_id="O2" value="20.8" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="14.79"/>
                    <measurement group_id="O2" value="21.4" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="12.06"/>
                    <measurement group_id="O2" value="20.3" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="12.07"/>
                    <measurement group_id="O2" value="23.2" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="13.18"/>
                    <measurement group_id="O2" value="25.3" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="114"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="14.23"/>
                    <measurement group_id="O2" value="37.4" spread="12.71"/>
                    <measurement group_id="O3" value="39.3" spread="12.23"/>
                    <measurement group_id="O4" value="40.1" spread="10.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="306"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="14.23"/>
                    <measurement group_id="O2" value="38.5" spread="18.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="15.43"/>
                    <measurement group_id="O2" value="36.4" spread="17.43"/>
                    <measurement group_id="O3" value="37.2" spread="14.19"/>
                    <measurement group_id="O4" value="42.0" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="270"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="13.47"/>
                    <measurement group_id="O2" value="38.2" spread="20.63"/>
                    <measurement group_id="O3" value="38.6" spread="10.90"/>
                    <measurement group_id="O4" value="41.1" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="244"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="12.90"/>
                    <measurement group_id="O2" value="38.5" spread="12.21"/>
                    <measurement group_id="O3" value="38.4" spread="9.91"/>
                    <measurement group_id="O4" value="42.0" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="13.42"/>
                    <measurement group_id="O2" value="37.6" spread="12.35"/>
                    <measurement group_id="O3" value="36.4" spread="14.36"/>
                    <measurement group_id="O4" value="41.5" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="234"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" spread="11.04"/>
                    <measurement group_id="O2" value="39.2" spread="22.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="12.79"/>
                    <measurement group_id="O2" value="39.7" spread="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="12.35"/>
                    <measurement group_id="O2" value="39.4" spread="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" spread="10.31"/>
                    <measurement group_id="O2" value="40.4" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7" spread="12.44"/>
                    <measurement group_id="O2" value="38.8" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="4.16"/>
                    <measurement group_id="O2" value="39.3" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Number of Participants Where MS or Its Treatments Resulted in Missed Work in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded whether their MS or its treatments caused them to miss work. Data is reported by part time or full time employment.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Number of Participants Where MS or Its Treatments Resulted in Missed Work in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded whether their MS or its treatments caused them to miss work. Data is reported by part time or full time employment.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="112"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="305"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="279"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="111"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="277"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="245"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="235"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Hours of Work Missed Due to MS or Its Treatment in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded the hours they missed work due to MS or its treatments. Data is reported by part time or full time employment.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants who missed work with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Hours of Work Missed Due to MS or Its Treatment in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participant recorded the hours they missed work due to MS or its treatments. Data is reported by part time or full time employment.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants who missed work with data available at the given timepoint.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="5.82"/>
                    <measurement group_id="O2" value="5.6" spread="4.93"/>
                    <measurement group_id="O3" value="12.0" spread="0"/>
                    <measurement group_id="O4" value="20.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="8.43"/>
                    <measurement group_id="O2" value="8.4" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="19.31"/>
                    <measurement group_id="O2" value="10.1" spread="3.63"/>
                    <measurement group_id="O3" value="8.3" spread="6.51"/>
                    <measurement group_id="O4" value="3.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="4.85"/>
                    <measurement group_id="O2" value="12.3" spread="12.83"/>
                    <measurement group_id="O3" value="4.5" spread="3.54"/>
                    <measurement group_id="O4" value="15.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="7.01"/>
                    <measurement group_id="O2" value="10.1" spread="13.05"/>
                    <measurement group_id="O3" value="16.0" spread="19.80"/>
                    <measurement group_id="O4" value="7.0" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="38.48"/>
                    <measurement group_id="O2" value="8.7" spread="12.02"/>
                    <measurement group_id="O3" value="5.0" spread="0.00"/>
                    <measurement group_id="O4" value="22.5" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="5.92"/>
                    <measurement group_id="O2" value="7.3" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.22"/>
                    <measurement group_id="O2" value="10.3" spread="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="7.90"/>
                    <measurement group_id="O2" value="5.3" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.14"/>
                    <measurement group_id="O2" value="9.0" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0"/>
                    <measurement group_id="O2" value="16.4" spread="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="11.42"/>
                    <measurement group_id="O2" value="15.0" spread="13.58"/>
                    <measurement group_id="O3" value="8.8" spread="11.39"/>
                    <measurement group_id="O4" value="8.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="10.13"/>
                    <measurement group_id="O2" value="7.9" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="13.80"/>
                    <measurement group_id="O2" value="12.4" spread="13.31"/>
                    <measurement group_id="O3" value="14.1" spread="16.27"/>
                    <measurement group_id="O4" value="7.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="15.50"/>
                    <measurement group_id="O2" value="11.7" spread="11.11"/>
                    <measurement group_id="O3" value="12.7" spread="15.57"/>
                    <measurement group_id="O4" value="6.7" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="11.51"/>
                    <measurement group_id="O2" value="7.6" spread="6.00"/>
                    <measurement group_id="O3" value="15.0" spread="17.54"/>
                    <measurement group_id="O4" value="8.7" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="13.19"/>
                    <measurement group_id="O2" value="16.1" spread="15.14"/>
                    <measurement group_id="O3" value="6.7" spread="2.89"/>
                    <measurement group_id="O4" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="13.88"/>
                    <measurement group_id="O2" value="10.7" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="14.32"/>
                    <measurement group_id="O2" value="13.1" spread="15.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="4.45"/>
                    <measurement group_id="O2" value="16.9" spread="15.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="11.94"/>
                    <measurement group_id="O2" value="10.0" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="13.98"/>
                    <measurement group_id="O2" value="11.2" spread="14.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="14.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Percent Impact on Employment in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participants assessed the percent impact of MS and its treatments on their work output using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything. Data is reported for part time or full time employment.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Percent Impact on Employment in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on employment. The participants assessed the percent impact of MS and its treatments on their work output using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything. Data is reported for part time or full time employment.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>percent impact</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="24.18"/>
                    <measurement group_id="O2" value="21.1" spread="26.16"/>
                    <measurement group_id="O3" value="19.0" spread="24.78"/>
                    <measurement group_id="O4" value="32.2" spread="34.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="24.06"/>
                    <measurement group_id="O2" value="16.0" spread="22.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="24.30"/>
                    <measurement group_id="O2" value="16.8" spread="22.84"/>
                    <measurement group_id="O3" value="26.5" spread="33.85"/>
                    <measurement group_id="O4" value="14.4" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="23.54"/>
                    <measurement group_id="O2" value="14.0" spread="23.03"/>
                    <measurement group_id="O3" value="18.8" spread="25.03"/>
                    <measurement group_id="O4" value="19.1" spread="24.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="27.63"/>
                    <measurement group_id="O2" value="18.8" spread="27.93"/>
                    <measurement group_id="O3" value="23.3" spread="29.50"/>
                    <measurement group_id="O4" value="11.1" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="24.01"/>
                    <measurement group_id="O2" value="16.8" spread="23.90"/>
                    <measurement group_id="O3" value="19.1" spread="23.80"/>
                    <measurement group_id="O4" value="22.3" spread="33.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="26.58"/>
                    <measurement group_id="O2" value="22.4" spread="30.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="23.16"/>
                    <measurement group_id="O2" value="15.3" spread="24.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" spread="33.82"/>
                    <measurement group_id="O2" value="15.3" spread="22.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="33.29"/>
                    <measurement group_id="O2" value="21.4" spread="25.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="27.73"/>
                    <measurement group_id="O2" value="20.3" spread="28.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="112"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="19.52"/>
                    <measurement group_id="O2" value="11.8" spread="24.02"/>
                    <measurement group_id="O3" value="13.9" spread="25.56"/>
                    <measurement group_id="O4" value="6.7" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="17.72"/>
                    <measurement group_id="O2" value="10.3" spread="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                    <count group_id="O2" value="276"/>
                    <count group_id="O3" value="111"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="20.13"/>
                    <measurement group_id="O2" value="8.3" spread="18.54"/>
                    <measurement group_id="O3" value="12.7" spread="25.79"/>
                    <measurement group_id="O4" value="11.2" spread="25.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="258"/>
                    <count group_id="O2" value="271"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="19.37"/>
                    <measurement group_id="O2" value="9.6" spread="21.75"/>
                    <measurement group_id="O3" value="12.2" spread="23.87"/>
                    <measurement group_id="O4" value="9.9" spread="24.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="21.40"/>
                    <measurement group_id="O2" value="7.8" spread="18.39"/>
                    <measurement group_id="O3" value="14.0" spread="23.47"/>
                    <measurement group_id="O4" value="11.3" spread="22.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="227"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="18.29"/>
                    <measurement group_id="O2" value="8.4" spread="18.59"/>
                    <measurement group_id="O3" value="11.1" spread="23.76"/>
                    <measurement group_id="O4" value="10.2" spread="24.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="230"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="13.87"/>
                    <measurement group_id="O2" value="8.6" spread="19.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="205"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="18.36"/>
                    <measurement group_id="O2" value="7.8" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="18.53"/>
                    <measurement group_id="O2" value="10.1" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="19.23"/>
                    <measurement group_id="O2" value="7.5" spread="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="22.36"/>
                    <measurement group_id="O2" value="9.3" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Time: Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="23.33"/>
                    <measurement group_id="O2" value="7.5" spread="18.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Hours of Household Chores Planned to Perform in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded their planned hours for household chores.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Hours of Household Chores Planned to Perform in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded their planned hours for household chores.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="585"/>
                    <count group_id="O2" value="597"/>
                    <count group_id="O3" value="219"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="10.87"/>
                    <measurement group_id="O2" value="10.0" spread="10.85"/>
                    <measurement group_id="O3" value="15.8" spread="13.68"/>
                    <measurement group_id="O4" value="11.5" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="596"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="11.38"/>
                    <measurement group_id="O2" value="12.2" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="561"/>
                    <count group_id="O3" value="227"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="11.75"/>
                    <measurement group_id="O2" value="12.6" spread="11.24"/>
                    <measurement group_id="O3" value="14.4" spread="13.66"/>
                    <measurement group_id="O4" value="11.1" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="552"/>
                    <count group_id="O2" value="538"/>
                    <count group_id="O3" value="213"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="11.43"/>
                    <measurement group_id="O2" value="12.6" spread="11.39"/>
                    <measurement group_id="O3" value="15.7" spread="14.74"/>
                    <measurement group_id="O4" value="11.6" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="514"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="12.10"/>
                    <measurement group_id="O2" value="13.9" spread="12.87"/>
                    <measurement group_id="O3" value="15.0" spread="13.55"/>
                    <measurement group_id="O4" value="12.3" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="486"/>
                    <count group_id="O2" value="461"/>
                    <count group_id="O3" value="191"/>
                    <count group_id="O4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="10.70"/>
                    <measurement group_id="O2" value="13.5" spread="12.10"/>
                    <measurement group_id="O3" value="14.8" spread="12.20"/>
                    <measurement group_id="O4" value="12.6" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="451"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="12.09"/>
                    <measurement group_id="O2" value="13.1" spread="12.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="412"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="12.89"/>
                    <measurement group_id="O2" value="13.4" spread="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="361"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="12.35"/>
                    <measurement group_id="O2" value="13.7" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="11.78"/>
                    <measurement group_id="O2" value="13.9" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="292"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="13.01"/>
                    <measurement group_id="O2" value="14.0" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="11.49"/>
                    <measurement group_id="O2" value="10.1" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Number of Participants Where MS or Its Treatments Kept the Participant From Completing Chores in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded whether MS or its treatments kept them from completing household chores.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Number of Participants Where MS or Its Treatments Kept the Participant From Completing Chores in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded whether MS or its treatments kept them from completing household chores.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="591"/>
                    <count group_id="O2" value="600"/>
                    <count group_id="O3" value="220"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="600"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="572"/>
                    <count group_id="O2" value="565"/>
                    <count group_id="O3" value="227"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="553"/>
                    <count group_id="O2" value="541"/>
                    <count group_id="O3" value="213"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="515"/>
                    <count group_id="O2" value="489"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="487"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="191"/>
                    <count group_id="O4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="439"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="427"/>
                    <count group_id="O2" value="413"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="362"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="331"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="299"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Hours Not Performing Household Chores Due to MS or Its Treatment in 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded the hours where they were not able to perform household chores due to MS or its treatments.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants unable to complete chores with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Hours Not Performing Household Chores Due to MS or Its Treatment in 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant recorded the hours where they were not able to perform household chores due to MS or its treatments.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants unable to complete chores with data available at the given timepoint.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="7.82"/>
                    <measurement group_id="O2" value="5.1" spread="5.08"/>
                    <measurement group_id="O3" value="5.4" spread="6.25"/>
                    <measurement group_id="O4" value="5.2" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="9.35"/>
                    <measurement group_id="O2" value="5.9" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="124"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="7.56"/>
                    <measurement group_id="O2" value="5.2" spread="4.59"/>
                    <measurement group_id="O3" value="5.7" spread="7.75"/>
                    <measurement group_id="O4" value="5.0" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="11.41"/>
                    <measurement group_id="O2" value="4.7" spread="3.53"/>
                    <measurement group_id="O3" value="7.9" spread="9.19"/>
                    <measurement group_id="O4" value="4.7" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="7.16"/>
                    <measurement group_id="O2" value="6.6" spread="10.32"/>
                    <measurement group_id="O3" value="6.8" spread="8.03"/>
                    <measurement group_id="O4" value="5.8" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.93"/>
                    <measurement group_id="O2" value="5.1" spread="4.67"/>
                    <measurement group_id="O3" value="8.1" spread="9.35"/>
                    <measurement group_id="O4" value="3.8" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="8.23"/>
                    <measurement group_id="O2" value="5.9" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="4.95"/>
                    <measurement group_id="O2" value="6.3" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="5.19"/>
                    <measurement group_id="O2" value="5.5" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="9.01"/>
                    <measurement group_id="O2" value="5.7" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="7.09"/>
                    <measurement group_id="O2" value="7.3" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="6.36"/>
                    <measurement group_id="O2" value="9.8" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRPQ: Percent Impact on Performing Household Chores in the 205MS303 Treatment Period</title>
        <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant assessed the percent impact of MS and its treatments on how much they accomplished using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything.</description>
        <time_frame>301-303: Baseline 303, Weeks 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240; 203-303 and 302-303: Baseline 303, Weeks 24, 48, 72, 96 in Study 303</time_frame>
        <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>HRPQ: Percent Impact on Performing Household Chores in the 205MS303 Treatment Period</title>
          <description>The HRPQ was used by the participant to assess the impact of MS or its treatments on performing household chores. The participant assessed the percent impact of MS and its treatments on how much they accomplished using a VAS where 0= MS or its treatments had no impact on how much I accomplished to 100=MS or its treatments kept me from accomplishing anything.</description>
          <population>ITT Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>percent impact</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="519"/>
                    <count group_id="O2" value="515"/>
                    <count group_id="O3" value="219"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="23.16"/>
                    <measurement group_id="O2" value="17.5" spread="25.31"/>
                    <measurement group_id="O3" value="25.3" spread="29.42"/>
                    <measurement group_id="O4" value="18.9" spread="24.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="587"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="24.40"/>
                    <measurement group_id="O2" value="17.5" spread="25.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="557"/>
                    <count group_id="O2" value="552"/>
                    <count group_id="O3" value="226"/>
                    <count group_id="O4" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="25.23"/>
                    <measurement group_id="O2" value="16.7" spread="24.71"/>
                    <measurement group_id="O3" value="25.5" spread="28.81"/>
                    <measurement group_id="O4" value="24.8" spread="30.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="541"/>
                    <count group_id="O2" value="531"/>
                    <count group_id="O3" value="210"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="25.48"/>
                    <measurement group_id="O2" value="17.1" spread="26.23"/>
                    <measurement group_id="O3" value="23.8" spread="28.52"/>
                    <measurement group_id="O4" value="21.0" spread="27.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="507"/>
                    <count group_id="O2" value="485"/>
                    <count group_id="O3" value="199"/>
                    <count group_id="O4" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="26.83"/>
                    <measurement group_id="O2" value="17.8" spread="26.13"/>
                    <measurement group_id="O3" value="25.4" spread="27.88"/>
                    <measurement group_id="O4" value="19.6" spread="23.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="482"/>
                    <count group_id="O2" value="455"/>
                    <count group_id="O3" value="187"/>
                    <count group_id="O4" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="25.39"/>
                    <measurement group_id="O2" value="17.7" spread="26.18"/>
                    <measurement group_id="O3" value="23.8" spread="29.07"/>
                    <measurement group_id="O4" value="21.4" spread="27.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="449"/>
                    <count group_id="O2" value="435"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="25.10"/>
                    <measurement group_id="O2" value="16.9" spread="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="421"/>
                    <count group_id="O2" value="411"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="24.40"/>
                    <measurement group_id="O2" value="17.4" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="356"/>
                    <count group_id="O2" value="358"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="26.03"/>
                    <measurement group_id="O2" value="18.2" spread="26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="26.55"/>
                    <measurement group_id="O2" value="17.3" spread="25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="26.11"/>
                    <measurement group_id="O2" value="18.3" spread="26.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="14.95"/>
                    <measurement group_id="O2" value="16.0" spread="26.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Assessments in the 205MS303 Treatment Period</title>
        <description>Clinical Laboratory assessments included tests of hematology, blood chemistry, renal function, and thyroid function. The investigator determined if the results were clinically significant.</description>
        <time_frame>Up to 4.6 years in 303</time_frame>
        <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Assessments in the 205MS303 Treatment Period</title>
          <description>Clinical Laboratory assessments included tests of hematology, blood chemistry, renal function, and thyroid function. The investigator determined if the results were clinically significant.</description>
          <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Tolerability as Assessed by Participant-reported Injection Site Pain VAS</title>
        <description>The VAS is a 10 cm-long horizontal line labeled with 2 extremes of pain at either end: 0 =no pain on the left and 100=very painful on the right. The participant rates their perceived pain of each injection by placing a vertical mark on the line to indicate the level of pain.</description>
        <time_frame>After the first and fourth injections in 303, approximately Week 0 and Week 12</time_frame>
        <population>Safety Population consisted of all participants who completed Study 301,203 or 302 and received at least one dose of DAC HYP in Study 303. Local tolerability of the DAC HYP injection was assessed for all participants who received DAC HYP in Study 303 with data available at the given timepoint and is independent of the treatment previously received.</population>
        <group_list>
          <group group_id="O1">
            <title>DAC HYP 150 mg</title>
            <description>All participants who received DAC HYP 150 mg SC injection in study 205MS303.</description>
          </group>
        </group_list>
        <measure>
          <title>Local Tolerability as Assessed by Participant-reported Injection Site Pain VAS</title>
          <description>The VAS is a 10 cm-long horizontal line labeled with 2 extremes of pain at either end: 0 =no pain on the left and 100=very painful on the right. The participant rates their perceived pain of each injection by placing a vertical mark on the line to indicate the level of pain.</description>
          <population>Safety Population consisted of all participants who completed Study 301,203 or 302 and received at least one dose of DAC HYP in Study 303. Local tolerability of the DAC HYP injection was assessed for all participants who received DAC HYP in Study 303 with data available at the given timepoint and is independent of the treatment previously received.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Injection, Post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection, Post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Local Tolerability Clinician Injection Site Assessment Categories</title>
        <description>The investigator assessed the injection site after the first dose and before the fourth dose for the presence of erythema (None, Mild, Moderate, Severe), pigmentation (None, Hypo, Hyper), Induration (None, Mild, Moderate, Severe), Tenderness (None, Mild, Moderate, Severe) and Temperature (Normal, Warm, Hot). The number of participants in each grade is reported.</description>
        <time_frame>After the first and fourth injections in 303, approximately Week 0 and Week 12</time_frame>
        <population>Safety Population included all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Local tolerability of the DAC HYP injection was assessed for all participants who received DAC HYP in Study 303 with data available at the given timepoint and is independent of the treatment previously received.</population>
        <group_list>
          <group group_id="O1">
            <title>DAC HYP 150 mg</title>
            <description>All participants who received DAC HYP 150 mg SC injection in study 205MS303.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Local Tolerability Clinician Injection Site Assessment Categories</title>
          <description>The investigator assessed the injection site after the first dose and before the fourth dose for the presence of erythema (None, Mild, Moderate, Severe), pigmentation (None, Hypo, Hyper), Induration (None, Mild, Moderate, Severe), Tenderness (None, Mild, Moderate, Severe) and Temperature (Normal, Warm, Hot). The number of participants in each grade is reported.</description>
          <population>Safety Population included all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Local tolerability of the DAC HYP injection was assessed for all participants who received DAC HYP in Study 303 with data available at the given timepoint and is independent of the treatment previously received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Injection Post-dose, Erythema: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Erythema: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Erythema: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Erythema: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Erythema: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Erythema: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Erythema: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Erythema: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Pigmentation: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Pigmentation: Hypo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Pigmentation: Hyper</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Pigmentation: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Pigmentation: Hypo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Pigmentation: Hyper</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Induration: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Induration: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Induration: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Induration: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Induration: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Induration: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Induration: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Induration: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Tenderness: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Tenderness: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Tenderness: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose, Tenderness: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Tenderness: None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Tenderness: Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Tenderness: Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Tenderness: Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose,Temperature: Normal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose,Temperature: Warm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Injection Post-dose,Temperature: Hot</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Temperature: Normal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Temperature: Warm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Injection Pre-dose, Temperature: Hot</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-BIIB019 Binding Antibodies (ADAbs) in the 205MS303 Treatment Period</title>
        <description>Blood samples were collected for ADAbs and were analyzed using a laboratory test. The number of participants ADAb positive at any post-baseline timepoint is reported.</description>
        <time_frame>Up to 4.6 years in the 303 Treatment Period</time_frame>
        <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number of participants analyzed is the number of participants with evaluable data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-BIIB019 Binding Antibodies (ADAbs) in the 205MS303 Treatment Period</title>
          <description>Blood samples were collected for ADAbs and were analyzed using a laboratory test. The number of participants ADAb positive at any post-baseline timepoint is reported.</description>
          <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number of participants analyzed is the number of participants with evaluable data for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-BIIB019 Neutralizing Antibodies (Nabs) in the 205MS303 Treatment Period</title>
        <description>Blood samples were collected for NAbs and were analyzed using a laboratory test. The number of participants NAb positive at any post-baseline timepoint is reported.</description>
        <time_frame>Up to 4.6 years in the 303 Treatment Period</time_frame>
        <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number of participants analyzed is the number of participants with evaluable data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94.1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
          </group>
          <group group_id="O4">
            <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-BIIB019 Neutralizing Antibodies (Nabs) in the 205MS303 Treatment Period</title>
          <description>Blood samples were collected for NAbs and were analyzed using a laboratory test. The number of participants NAb positive at any post-baseline timepoint is reported.</description>
          <population>Safety Population consisted of all participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number of participants analyzed is the number of participants with evaluable data for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From 205MS303 Baseline in the Symbol Digit Modalities Test (SDMT) Score in the 205MS303 Treatment Period</title>
        <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline 303, Weeks 144, 168, 192, 240 in 303</time_frame>
        <population>ITT Population: All participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data is collected for participants from 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From 205MS303 Baseline in the Symbol Digit Modalities Test (SDMT) Score in the 205MS303 Treatment Period</title>
          <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.</description>
          <population>ITT Population: All participants who completed Study 301, 203 or 302 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data is collected for participants from 203 and 302 studies.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="15.13"/>
                    <measurement group_id="O2" value="52.4" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="321"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="11.38"/>
                    <measurement group_id="O2" value="-3.5" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="11.59"/>
                    <measurement group_id="O2" value="-3.7" spread="13.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="12.02"/>
                    <measurement group_id="O2" value="-2.8" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="10.78"/>
                    <measurement group_id="O2" value="-2.0" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From 205MS301 Baseline in the SDMT Score in the 205MS301-303 Combined Study Period</title>
        <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline 301, Weeks 24, 48, 72, 96, 120, 144 in 301; Weeks 144, 168, 192, 216, 240 in 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From 205MS301 Baseline in the SDMT Score in the 205MS301-303 Combined Study Period</title>
          <description>SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best). A positive change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least one dose of DAC HYP in Study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="577"/>
                    <count group_id="O2" value="584"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="16.18"/>
                    <measurement group_id="O2" value="48.4" spread="16.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 24 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="572"/>
                    <count group_id="O2" value="575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="11.20"/>
                    <measurement group_id="O2" value="1.1" spread="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 48 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="12.31"/>
                    <measurement group_id="O2" value="2.2" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 72 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="573"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="13.12"/>
                    <measurement group_id="O2" value="3.6" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 96 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="574"/>
                    <count group_id="O2" value="579"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="13.04"/>
                    <measurement group_id="O2" value="4.1" spread="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 120 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="416"/>
                    <count group_id="O2" value="437"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="13.53"/>
                    <measurement group_id="O2" value="5.4" spread="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 144 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="13.38"/>
                    <measurement group_id="O2" value="6.6" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 144 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="14.95"/>
                    <measurement group_id="O2" value="1.3" spread="13.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 168 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="14.78"/>
                    <measurement group_id="O2" value="1.6" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 192 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                    <count group_id="O2" value="302"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="15.81"/>
                    <measurement group_id="O2" value="2.1" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 216 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="15.91"/>
                    <measurement group_id="O2" value="4.5" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 at Week 240 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="11.41"/>
                    <measurement group_id="O2" value="8.8" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS303 Treatment Period</title>
        <description>The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline 303, Weeks 12, 24, 48, 120, 144, 168, 192, 216, 240 in 303</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS303 Treatment Period</title>
          <description>The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed Study 301 and received at least 1 dose of DAC HYP during Study 303. Number analyzed is the number of participants with data available at the given timepoint. No data was collected for participants from the 203 and 302 studies.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="595"/>
                    <count group_id="O2" value="604"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" lower_limit="0" upper_limit="60"/>
                    <measurement group_id="O2" value="54.0" lower_limit="3" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="584"/>
                    <count group_id="O2" value="584"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-40" upper_limit="19"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-23" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="564"/>
                    <count group_id="O2" value="557"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-26" upper_limit="26"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-27" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="530"/>
                    <count group_id="O2" value="509"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-41" upper_limit="21"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-21" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-3" upper_limit="-3"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="301"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-34" upper_limit="23"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-31" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-35" upper_limit="21"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-33" upper_limit="26"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-42" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                    <count group_id="O2" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-22" upper_limit="16"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-23" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8" upper_limit="12"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-9" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3813</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1679</p_value>
            <method>ANOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 48</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5634</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 144</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7003</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 168</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7812</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 192</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3246</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 216</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6423</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change to Week 240</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0288</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS301-303 Combined Study Period</title>
        <description>The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline 301, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 in the 301 study, Baseline 303, Weeks 12, 24, 48, 120, 144,168, 192, 216, 240 in 303 study</time_frame>
        <population>301-303 ITT Population consisted of all participants who completed study 301 and had at least 1 dose of DAC HYP during study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
            <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
            <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS301-303 Combined Study Period</title>
          <description>The PASAT 3 assesses auditory information processing speed. A random series of numbers from 1 to 9, inclusive, are presented and the participant is instructed to consecutively add pairs of numbers so that each number is added to the one that immediately preceded it. In the 3- second PASAT, numbers are presented at a rate of 1 every 3 seconds. The total possible score is the number of correct responses from 0 to 60 (best). A positive change from baseline indicates improvement.</description>
          <population>301-303 ITT Population consisted of all participants who completed study 301 and had at least 1 dose of DAC HYP during study 303. Number analyzed is the number of participants with data available at the given timepoint.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="606"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                    <count group_id="O2" value="605"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="0" upper_limit="60"/>
                    <measurement group_id="O2" value="51.0" lower_limit="9" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 12 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="593"/>
                    <count group_id="O2" value="603"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-58" upper_limit="40"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-59" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 24 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="594"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-26" upper_limit="31"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-32" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 36 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="594"/>
                    <count group_id="O2" value="599"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-29" upper_limit="30"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-37" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 48 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="602"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-25" upper_limit="42"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-38" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 60 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="599"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-46" upper_limit="40"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-34" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 72 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="592"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-20" upper_limit="40"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-21" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 84 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="591"/>
                    <count group_id="O2" value="598"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-31" upper_limit="39"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-41" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 96 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="594"/>
                    <count group_id="O2" value="600"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-28" upper_limit="41"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-25" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 108 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="489"/>
                    <count group_id="O2" value="500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-27" upper_limit="43"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-25" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 120 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-27" upper_limit="35"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-31" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 132 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="289"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-30" upper_limit="35"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-19" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 144 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-25" upper_limit="31"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-21" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 156 for 301</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-4.0" lower_limit="-4" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Baseline 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="595"/>
                    <count group_id="O2" value="603"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-34" upper_limit="44"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-41" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 12 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="580"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-38" upper_limit="43"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-26" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 24 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="562"/>
                    <count group_id="O2" value="553"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-31" upper_limit="40"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-27" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 48 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="528"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-47" upper_limit="44"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-24" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 120 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="15" upper_limit="15"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 144 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="303"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-32" upper_limit="37"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-24" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 168 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-36" upper_limit="42"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-29" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 192 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="316"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-40" upper_limit="42"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-21" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 216 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                    <count group_id="O2" value="277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="-27" upper_limit="40"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-30" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline 301 to Week 240 for 303</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-10" upper_limit="26"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 12 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2567</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 24 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6152</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 36 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2024</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 48 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9988</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 60 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7962</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 72 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8486</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 84 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4478</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 96 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3250</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 108 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1290</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 120 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7295</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 132 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8647</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 144 for 301</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2183</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Baseline 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3945</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 12 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5068</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 24 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1669</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 48 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5038</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 144 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6001</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 168 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8617</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 192 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2590</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 216 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5159</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline 301 to Week 240 for 303</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6123</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ranks and adjusted for the baseline raw score, baseline age (&lt;=35 vs &gt;35) and history of prior IFN beta.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug in study 205MS303 to within 180 days of last dose (up to approximately 5.5 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IFN β-1a 30 µg (301)/DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 4.6 years in this long-term extension study 303; includes participants who previously received IFN β-1a 30 µg IM injection once weekly in study 301 every 4 weeks for up to 144 weeks.</description>
        </group>
        <group group_id="E2">
          <title>DAC HYP 150 mg (301) /DAC HYP 150 mg (303)</title>
          <description>Daclizumab High Yield Process (DAC HYP)150 mg subcutaneous (SC) injection every 4 weeks for up to 4.6 years in this long-term extension study 205MS303 (303); includes participants who previously received DAC HYP 150 mg SC injection in Study 205MS301 (301) every 4 weeks for up to 144 weeks.</description>
        </group>
        <group group_id="E3">
          <title>DAC HYP 150 mg (302) /DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 93.7 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS302 (302) every 4 weeks for up to 24 weeks followed by a 20-week washout period then continued treatment for up to an additional 3 years.</description>
        </group>
        <group group_id="E4">
          <title>DAC HYP 150 mg (203) /DAC HYP 150 mg (303)</title>
          <description>DAC HYP 150 mg SC injection every 4 weeks for up to 94. 1 weeks in this long-term extension study 303 (participants started at Week 144 of the study); includes participants who previously received DAC HYP 150 mg SC injection in study 205MS203 (203) every 4 weeks for up to 288 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pseudolymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gingivitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Stomatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tongue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hepatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Brucellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis c</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hepatitis e</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Reiter's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ligament laxity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Seronegative arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Still's disease adult onset</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Systemic sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Anorectal human papilloma virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Metaplastic breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Testicular neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Uterine leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bipolar i disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urogenital fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ovarian adhesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pharyngeal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tracheal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia scarring</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Perivascular dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pityriasis rosea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Granulomatosis with polyangiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="463" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="476" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="606"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Study Medical Director</name_or_title>
      <organization>Biogen</organization>
      <phone>866-633-4636</phone>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

